Showing results (171-180 of 280) with videos related to
Sort By:
Pageof 28
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 26, 2007
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinomaDavid E Avigan, Baldev Vasir, Daniel J George, et al.Urologic Oncology|October 22, 2016
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancerMatthew I Milowsky, Matthew D Galsky, Michael J Morris, et al.Cancer|May 26, 2026
Genetic ancestry-concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration-resistant prostate cancerSean A Piwarski, Lauren E Howard, Morgan A Paul, et al.Prostate Cancer and Prostatic Diseases|February 22, 2022
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)Daniel J George, Neeraj Agarwal, Oliver Sartor, et al.Cancer Medicine|July 5, 2019
Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancerMatthew D Tucker, Jason Zhu, Daniele Marin, et al.JCO Clinical Cancer Informatics|August 13, 2019
Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data SetSandra D Griffith, Rebecca A Miksad, Geoff Calkins, et al.Cancer Chemotherapy and Pharmacology|February 27, 2017
Phase I study of pazopanib plus TH-302 in advanced solid tumorsRichard F Riedel, Kellen L Meadows, Paula H Lee, et al.The Oncologist|August 11, 2019
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trialDaniel J George, Colin Hessel, Susan Halabi, et al.Prostate Cancer and Prostatic Diseases|June 20, 2026
Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trialQuoc-Dien Trinh, Daniel J George, Neal Shore, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2017
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN TrialToni K Choueiri, Susan Halabi, Ben L Sanford, et al.Pageof 28